Drug Type Biosimilar, Monoclonal antibody |
Synonyms Omalizumab biosimilar, 奥马佐单抗生物类似药 (中央研究院), FB-317 |
Target |
Action inhibitors |
Mechanism IgE inhibitors(Immunoglobulin E inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Allergic asthma | Phase 1 | Taiwan Province | 30 Jan 2022 | |
| Chronic Urticaria | Phase 1 | Taiwan Province | 30 Jan 2022 | |
| Asthma | Phase 1 | - | - | |
| Asthma | Phase 1 | - | - | |
| Urticaria | Phase 1 | - | - | |
| Urticaria | Phase 1 | - | - |






